Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomised, double-blindplacebo- controlled trial

Gut

Volumn 61, Issue 12, 2012, Pages 1693-1700

  Hueber, Wolfgang ^a   Sands, Bruce E ^b   Lewitzky, Steve ^c   Vandemeulebroecke, Marc ^a   Reinisch, Walter ^d   Higgins, Peter D R ^e   Wehkamp, Jan ^f   Feagan, Brian G ^g   Yao, Michael D ^h   Karczewski, Marek ⁱ   Karczewski, Jacek ⁱ   Pezous, Nicole ^a   Bek, Stephan ^a   Bruin, Gerard ^a   Mellgard, Bjoern ^a   Berger, Claudia ^a   Londei, Marco ^j   Bertolino, Arthur P ^a   Tougas, Gervais ^a   Travis, Simon P L ^k  

^a NOVARTIS PHARMA AG   (Switzerland)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF MICHIGAN   (United States)

^f ROBERT BOSCH HOSPITAL   (Germany)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

ⁱ Solumed Research Unit   (Poland)

^j GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^k UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CALGRANULIN; INTERLEUKIN 17; MERCAPTOPURINE; METHOTREXATE; PLACEBO; PREDNISOLONE; SECUKINUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIKE LIGAND 1A; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ALLELE; APHTHOUS STOMATITIS; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANDIDIASIS; CONTROLLED STUDY; CROHN DISEASE; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOKALEMIA; HYPOTENSION; ILEOSTOMY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MYALGIA; MYCOSIS; NAUSEA; NEUTROPENIA; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PILONIDAL SINUS; PRIORITY JOURNAL; PROBABILITY; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BAYES THEOREM; BIOLOGICAL MARKERS; CROHN DISEASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENETIC MARKERS; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-17; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; YOUNG ADULT;

EID: 84868680312     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-301668     Document Type: Article

References (40)

1. Burger D, Travis S. Conventional medical management of inflammatory bowel disease. Gastroenterology 2011;140:1827-37.e2.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9. (Pubitemid 34621118)
3. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65. (Pubitemid 46108762)
4. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Enql J Med 2007; 357:239-50. (Pubitemid 47080388)
5. Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, et al. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet 2008;372:67-81. (Pubitemid 351902263)
6. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006;116: 1310-16.
7. Elson CO, Cong Y, Weaver CT, et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 2007;132:2359-70. (Pubitemid 46890867)
8. Kullberg MC, Jankovic D, Feng CG, et al . IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J Exp Med 2006;203:2485-94. (Pubitemid 44664618)
9. O'Connor W Jr, Kamanaka M, Booth CJ, et al . A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol 2009;10:603-9.
10. Becker C, Domhoff H, Neufert C, et al. Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J Immunol 2006;177:2760-4. (Pubitemid 44277789)
11. Ogawa A, Andoh A, Araki Y, et al. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol 2004;110:55-62. (Pubitemid 38177420)
12. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003;52:65-70. (Pubitemid 36020767)
13. Holtta V, Klemetti P, Sipponen T, et al. IL-23/IL-17 immunity as a hallmark of Crohn's disease. Inflamm Bowel Dis 2008;14:1175-84.
14. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314 :1461-3. (Pubitemid 44871953)
15. Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet 2007;39:830-2. (Pubitemid 47014496)
16. Barrett JC, Hansoul S, Nicolae DL, et al . Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008;40:955-62.
17. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Enql J Med 2007;351:2069-79.
18. Sandborn WJ, Feagan BG, Fedorak RN, et al Ustekinumab Crohn's Disease Study Group. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008;135:1130-41.
19. Hueber W, Patel DD, Dryja T, et al Uveitis Study Group. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010;2:52-72.
20. Travis SP, Stange EF, Lémann M, et al; European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006;55(Suppl 1):i16-35. (Pubitemid 43268291)
21. Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007;39:596-604. (Pubitemid 46676115)
22. Spiegelhalter D, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-care Evaluation. Chichester, UK: John Wiley & Sons, 2004. ISBN:978-0-471- 49975-6.
23. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33.
24. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;120:1330-8. (Pubitemid 32322306)
25. Sandborn WJ, Feagan BG, Hanauer SB, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebocontrolled trial. Gastroenterology 2001;120:1330-8. (Pubitemid 32322306)
26. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146:829-38. (Pubitemid 351650483)
27. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357 :228-38. (Pubitemid 47080387)
28. Winter TA, Wright J, Ghosh S, et al. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Aliment Pharmacol Ther 2004;20 :1337-46. (Pubitemid 40040081)
29. Neuenschwander B, Capkun-Niggli G, Branson M, et al. Summarizing historical information on controls in clinical trials. Clin Trials 2010;7:5-18.
30. Strober W, Zhang F, Kitani A, et al. Proinflammatory cytokines underlying the inflammation of Crohn's disease. Curr Opin Gastroenterol 2010;26:310-17.
31. Genovese MC, Durez P, Richards HB, et al. One Year efficacy and safety results of a phase II trial of secukinumab in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2011;63:S149-150.
32. Rich PA, Sigurgeirsson B, Thaci PD, et al. Secukinumab, A New Fully Human Monoclonal Anti-Interleukin-17A Antibody, in the Treatment of Moderate-to- severe Plaque Psoriasis: Interim Efficacy and Safety Data from a Phase II Regimen-finding Trial. 20th Congress of the European Academy of Dermatology and Venereology; October 21, 2011. Lisbon, Portugal. Abstract 0627. ISBN# 9789892026091.
33. Puel A, Döffinger R, Natividad A, et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 2010;207 :291-7.
34. Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011;332:65-8.
35. Liu L, Okada S, Kong XF, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 2011;208 :1635-48.
36. Vinh D. Insights into human antifungal immunity from primary immunodeficiencies. Lancet Infect Dis 2011;11:780-92.
37. Toedter GP, Blank M, Lang Y, et al . Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. Am J Gastroenterol 2009;104:2768-73.
38. Sandborn WJ, Gasink C, Gao LL, et al. A Multicentre, Randomized, Double-blind, Placebo-controlled Phase 2b Study of Ustekinumab, A Human Monoclonal Antibody to IL-12/23p40 in Patients with Moderately to Severely Active Crohn's Disease: Results Through Week 22 from the CERTIFI trial DDW 2011. Gastroenterology 2011;140(Suppl 1):S-109.
39. Thiebaut R, Kotti S, Jung C, et al . TNFSF15 polymorphisms are associated with susceptibility to inflammatory bowel disease in a new European cohort. Am J Gastroenterol 2009;104:384-91.
40. Kamada N, Hisamatsu T, Honda H, et al. TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease. Inflamm Bowel Dis 2010;16:568-75.